Central IRB Review Is an Essential Requirement for Cancer Clinical Trials

Journal of Law, Medicine and Ethics 45 (3):341-347 (2017)
  Copy   BIBTEX

Abstract

There are compelling medical, ethical, and legal arguments that support mandating use of a central institutional review board for the review of clinical trials performed at multiple institutional sites. Progress against serious diseases depends on this.

Categories

Add categories

Keywords

Reprint years

DOI

10.1177/1073110517737532

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,369

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Clinical Equipoise: Actual or Hypothetical Disagreement?Scott Gelfand - 2013 - Journal of Medicine and Philosophy 38 (6):590--604.
Problems associated with randomized controlled clinical trials in breast cancer.Ann E. Johnson - 1998 - Journal of Evaluation in Clinical Practice 4 (2):119-126.
Do Patients with Breast Cancer Participating in Clinical Trials Receive Better Nursing Care?Myriam Skrutkowska & Charles Weijer - unknown
Riposte to Guest Commentaries on 'Problems associated with randomized controlled clinical trials in breast cancer'.Ann E. Johnson - 1998 - Journal of Evaluation in Clinical Practice 4 (3):231-236.
Between Bench and Bedside: Science, Healing, and Interleukin-2 in a Cancer Ward.Ilana Löwy - 1996 - Harvard University Press.
Looking toward the future of clinical trials: The application of communication variables to the recruitment of women into breast cancer clinical trials.Anne P. Hubbell, Lisa Murray, Wen‐Ying Liu & Kim Witte - 2001 - World Futures 57 (6):599-613.
What do primary care nurses and radiation therapists in a Canadian cancer centre think about clinical trials?Joanna E. M. Sale - 2007 - Journal of Evaluation in Clinical Practice 13 (2):186-191.
The Poster Child for the Need for Central Review of Research Protocols: The Children's Oncology Group.Rebecca D. Pentz & Anita F. Khayat - 2004 - Cambridge Quarterly of Healthcare Ethics 13 (4):359-365.
Evaluating the Risks and Benefits of Phase II and III Clinical Cancer Trials: A Look at Institutional Review Board Members in the Netherlands.H. van Luijn, A. Musschenga, R. Keus & N. Aaronson - 2007 - IRB: Ethics & Human Research 29 (1).
Attitudes towards clinical research among cancer trial participants and non-participants: an interview study using a Grounded Theory approach.S. M. Madsen, S. Holm & P. Riis - 2007 - Journal of Medical Ethics 33 (4):234-240.
Bioethics and Cancer: When the Professional Becomes Personal.Rebecca Dresser - 2011 - Hastings Center Report 41 (6):14-18.
Uncertainty and the ethics of clinical trials.Sven Ove Hansson - 2006 - Theoretical Medicine and Bioethics 27 (2):149-167.
Commentary on'Problems associated with randomised controlled clinical trials in breast cancer'.M. Baum - 1998 - Journal of Evaluation in Clinical Practice 4:127-128.
Commentary on'Problems associated with randomized controlled clinical trials in breast cancer'.W. J. Cunliffe - 1998 - Journal of Evaluation in Clinical Practice 4:129-130.
The assessment of the risk - benefit ratio of phase II cancer clinical trials by Institutional Review Board members.A. W. Musschenga - unknown

Analytics

Added to PP
2017-10-25

Downloads
8 (#1,324,279)

6 months
4 (#798,692)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Controversies in Clinical Research Ethics.Robert M. Sade - 2017 - Journal of Law, Medicine and Ethics 45 (3):291-294.

Add more citations

References found in this work

No references found.

Add more references